p38 MAPK inhibitors: a patent review (2012 – 2013)

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.24, Iss.5, 2014-05, pp. : 535-554

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

p38α mitogen-activated protein kinase inhibitors, a patent review (2005 – 2011)

By Fischer Stefan Koeberle Solveigh C Laufer Stefan A

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 12, 2011-12 ,pp. : 1843-1866

Informa Healthcare

Access to resources Recommend Favorite

Glycogen phosphorylase inhibitors: a patent review (2008 - 2012)

By Gaboriaud-Kolar Nicolas Skaltsounis Alexios-Leandros

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 8, 2013-08 ,pp. : 1017-1032

Informa Healthcare

Access to resources Recommend Favorite

Osteoclast differentiation inhibitors: a patent review (2008 – 2012)

By Kim Seong Hwan Moon Seong-Hee

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 12, 2013-12 ,pp. : 1591-1610

Informa Healthcare

Access to resources Recommend Favorite

Mechanisms of the joint-protective effects of p38 MAPK inhibitors in rodent arthritis

By Mbalaviele Gabriel Monahan Joseph B

Expert Opinion on Drug Discovery, Vol. 3, Iss. 2, 2008-02 ,pp. : 163-172

Informa Healthcare

Access to resources Recommend Favorite

The Potential of p38 MAPK Inhibitors to Modulate Periodontal Infections

Current Drug Metabolism, Vol. 10, Iss. 1, 2009-01 ,pp. : 55-67

Bentham Science Publishers

Access to resources Recommend Favorite